Annals of Oncology

Article	Citations
415P Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sid	887
Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu	840
1246P A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients	770
821P Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma	644
LBA65 SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, op	612
212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?	605
123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial	551
ESMO pays tribute to Professor José Baselga	485
588P Androgen changes after enzalutamide or abiraterone plus prednisone in men with castration-resistant prostate cancer (HEAT): Results from a randomised clinical trial	417
O8-4 Siteless study for feasibility of electronic patient-reported outcome (ePRO) collection system in oncology	397
O13-4 Tepotinib safety in MET exon 14 (METex14) skipping NSCLC: Updated results from the VISION trial	392
111P A study on the relationship between tumor fusion burden (TFB) and tumor immune microenvironment	375
118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella	374
P-167 Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients	366
140P Benefit of adjuvant chemotherapy in luminal A-like early breast cancer in women aged 40 years or younger: Results of a national multi-institutional study	366
1651P Phase I study of ramucirumab in combination with irinotecan plus cisplatin in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)	360
P-111 Increased risk of pancreatic cancer among 141,387 diabetic patients treated with DPP-4 inhibitors analyzed with common data model	337
P-199 Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy	328
P-201 Retrospective evaluation of patients with colorectal cancer with metastasis in the central nervous system: Clinical and epidemiological prognostic factors	316
JS5-5 Onco-cardiology: Collaboration and task sharing for oncologist and cardiologist	313
801P Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma	305
PSY1-5 Precision medicine in gynecological cancer	287
839P Physician considered treatment attributes for third-line diffuse-large B-cell lymphoma treatment decision-making: Physician perspectives from a survey across Western Europe and US	284
P-64 The impact of sarcopenia on overall survival among cholangiocarcinoma patients: A systematic review and meta-analysis	283
31P Sulfhydryl groups in estrogen receptors	275

1803P The differences of TMB scores could be found in patients with different tumor types or pathological types	275
P-217 The knowledge and awareness for colorectal cancer in advanced colorectal cancer patients in China: A national multicenter study	271
P-332 Characteristic and clinical outcome of localized gastric cancer; real-world data	268
Notice and Disclaimer	267
P-362 Retrospective analysis of metastatic colorectal cancer based on clinical cancer registry data. Tumor biology, treatment, and outcome	258
P-379 ARID1A as a prognostic biomarker in gastroesophageal cancer: A genomic database analysis	246
1692P Thromboprophylaxis in high-risk oncology patients: Is it a safe and effective clinical decision-intervention?	217
1520P Preferences on treatment decision making in sarcoma patients. Prevalence and associated factors: Results from the PROSa study	215
1483P Cell-free DNA dominant clone allele frequency associates with poor outcomes in advanced pancreatic cancer	211
1712P Safety and efficacy of influenza and pneumococcal vaccines in cancer patients on active therapy: A prospective study	211
1482P Landscape of germline pathogenic variants beyond BRCA in pancreatic cancer patients	201
404P Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India	200
1481P Predictors for 30-day readmission in patients with pancreatic cancer who had DNR code status	198
50P Clinical characteristics, treatment patterns and outcomes of EGFR exon 20 insertion and other EGFR mutations in Korean aNSCLC patients	197
461P Spectrum of immune related adverse events (irAE) on treatment with checkpoint inhibitors and its association with survival: A real-world experience from India	196
431P Alveolar soft part sarcomas: A tertiary care Indian centre experience	196
720P Integrative genomic analysis of matched primary and recurrent tumors reveals molecular characteristics of hepatocellular carcinoma with short-term recurrence	182
P30-10 Prevention of chemotherapy-induced peripheral neuropathy by compression therapy	178
P49-4 Thyroid dysfunction associated with immune checkpoint blockade: An emerging immune-related adverse event	175
1583P COVID-19 related risk in patients enrolled in early-phase clinical trials	171
1164P Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315)	166
1186TiP EPONA, efficacy of osimertinib with platinum and pemetrexed in EGFR mutant non-small cell lung cancer patients bearing CNS metastasis, and have systemic progression but stable intracranial dis	163
P-32 Risk factors for early recurrence after radical gastrectomy followed by adjuvant chemotherapy for stage II or III gastric cancer: A multicenter, retrospective study	163
70P Genetic alterations and immune cell infiltration with potential impact on PD-(L)1 targeted treatment in various cancer entities: Biobank research project of the INFINITY registry	162
P-404 Survival outcomes and prognostic factors in high risk locally advanced rectal cancers (LARC) undergoing concurrent capecitabine and long course radiation (Cape – RT) – results of a large cohort	160
39P Clinical relevance of alterations in cancer (CRAC): A DB for selecting biomarkers for molecularly matched therapy in cancer patients	159
P53-4 Metastatic prostate cancer mimicking a rectal cancer: A case report	157
347MO 5-Aminolevulinic acid sonodynamic therapy in recurrent glioblastoma: A first-in-human phase 0/1 clinical trial	157
P58-7 Aortitis after the use of granulocyte colony stimulating factors: A case of right lower gingival carcinoma	157
P55-6 Encorafenib for Erdheim-Chester disease harboring the BRAFV600E mutation	157
651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)	152
677P Immunotherapy vs sunitinib as first-line treatment for advanced renal cell carcinoma in favourable risk patients: A meta-analysis of randomized clinical trials	147
355P Butterfly glioblastoma: Treatment strategies and clinical outcome	146
SO-20 Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study	142
P-7 How much can GIT cancer patients afford for effective and safe treatment?	142
P-160 Primary gastrointestinal lymphoma in Latin American patients. A 10-year follow-up	139
CN14 Cancer prevention awareness among Croatian AYA population	137
CN28 Impact of serious illness care program to patients with hematopoietic stem cell transplantation on goals of care documentation and acute healthcare utilization	135
P-173 Understanding the treatment algorithm of patients with advanced G2 gastroenteropancreatic neuroendocrine neoplasms: A single-institution retrospective analysis	134
83TiP Clinical implications of clonal hematopoiesis mutations in patients with solid tumors	129
Journal Information	128
P-177 Sex differences in chemotherapy-induced toxicities in gastric cancer patients	128
P-184 Prognostic value of mTOR expression and mismatch repair gene profile in advanced gastric and gastro-oesophageal cancer	125
342P A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients	124
336P Prognostic and predictive value of Immunoscore in stage III colorectal cancer in the combined SCOT and IDEA-HORG studies	119
MO9-8 Development of a data management system for comprehensive genomic profiling tests	118
137P Phase I dose-finding study of a novel anti-CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors	116
1012P Intratumoral immunotherapy with a novel TLR1/2/3 agonist, L-pampo, induces robust anti-tumor immune responses and enhances immune checkpoint blockade	116
1006P ACE1702, a first-in-class, off-the-shelf, selected natural killer cell [oNK] product using antibody cell conjugation technology [ACC], with pre-clinical and early clinical activity in HER2 <	116
139P First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal	115

202TiP A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibito	114
MO21-1 Prognostic value of pneumonitis after durvalumab in locally-advanced non-small cell lung cancer	113
O7-4 Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to 1st-line treatment with anti-EGFR antibody: JACCRO CC-16	113
1295TiP Investigation of calcium electroporation (CaEP) therapy in malignant cutaneous and subcutaneous tumours: A non-randomized phase II clinical trial of a novel palliative therapy	112
37P Development of splice switching antisense oligonucleotides targeting midkine	110
121P Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data	109
52P HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer - Impact of single-heterozygous UGT1	108
140P Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience	107
P-202 Topical diclofenac in prevention of capecitabine-associated HFS in patients with GI cancers: An exploratory subgroup analysis of the D-ToRCH study	106
1076P Cancer cachexia associated with gut microbiota and clinical outcomes of patients with non-small cell lung cancer amenable to immunotherapy	105
12P Any size of lymph node metastasis should be considered N1 in patients with cervical cancer	103
LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation	103
Title Page	103
11P Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer	102
P-225 Appraising the potential causal relationships between gut microbiota and colorectal cancer: A two-sample Mendelian randomization analysis	102
P-233 Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study, updated with new data	102
553P Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: Descriptive analysis of the	101
554P Does the type of hysterectomy affect the survival of patients with clinical IA endometrial cancer: A multicenter and retrospective study	99
1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized tria	94
1627P Management of locally advanced rectal cancer during the COVID-19 outbreak: First results of a shift towards short course neoadjuvant radiotherapy	92
1863P Incidence and predictors of severe adverse events during anti-PD-1 treatment	92
MO38-2 Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumors	92
1642P Improve the conditions of lockdown may decrease anxiety among cancer patients during the COVID-19 pandemic	90
350P Primary prevention of chemotherapy-induced neutropenia in patients with advanced lung cancer in real-world research	90
1474P Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)	88
1485O Percutaneous uterine needle biopsy with microscopic and array-CGH analyses in patients with suspicious myometrial tumors on MRI: A prospective study	83
1133P Whole genome sequencing can classify diagnostically challenging tumors	83
373P Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2	82
MO45-3 The efficacy of osimertinib in patients with EGFR-positive non-small cell lung cancer with malignant pleural effusion	82
51P Novel platform combines pathology and transcriptomics for a multi-scale analysis and visualization of the breast tumor heterogeneity	81
44P Breast cancer subtypes in Georgia: Higher frequency of triple-negative breast cancer compared to resource-rich areas	81
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy	80
P-42 How to improve outcome in high-risk stage III colon cancer with dMMR gene	80
1233P EGFR-TKIs compared with radiotherapy for patients of stage IV lung adenocarcinoma with EGFR mutation	79
470P Genomic landscape and its correlations with immunotherapy-related biomarkers in Chinese colorectal cancer patients	79
SY01-1 Novel therapies and Immunotherapy for small cell lung cancer: Finally, some progress	78
SY12-3 Precision medicine for esophageal cancer	78
105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approaches	77
1704P Multimodal approach to discover novel targets for antibody-drug conjugates by analyzing distinct expression patterns of frequent copy number aberration	77
1366TiP Tepotinib + osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2	76
P-85 Treatment propensity and the feasibility of cisplatin plus gemcitabine in elderly patients aged ≥ 75 years with biliary tract cancer	75
P73-4 Experience with nivolumab in advanced metastatic gastric cancer	75
147P Chemo-immunotherapy with or without consolidative radiotherapy in extensive-stage small cell lung cancer: An initial report of clinical outcome and safety	74
1640TiP PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC)	74
461P Molecular tumor profiling and matched molecular targeted treatment in metastatic young-onset colorectal cancer (YOCR)	74
1225P The progression-free survival of the first-line EGFR-TKI is a strong prognosticator of the second-line osimertinib in non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation: A real	73
1224P Systematic review and meta-analysis of immunotherapy effectiveness for pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertions	73
201P Metastatic and survival characteristics of de novo versus relapsed breast cancer in females aged>35-years-old: A nationwide multicenter study based on hospital population	73
224P Adherence to adjuvant hormonal therapy in patients with localized breast cancer	72
159P Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma	71
1046P Homologous recombination deficiency (HRD) and genomic associations in non-small cell lung cancer (NSCLC) using a novel HRD signature (HRDsig)	71
238P Budget impact analysis for the health care package by using MammaPrint in Belgium	71
ME07 New treatment strategy for hepatobiliary cancer	70
1310MO Neoadjuvant platinum-based chemotherapy (NAPC) for metastatic penile squamous cell carcinoma (PSCC): An international, multicenter, real-world study	70
1775P Prevalence of PD-L1 high expression in advanced urothelial carcinoma (aUC): Results from the PREVAIL prospective cohort study	70
972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial	70
P18-2 Clinical usefulness of universal screening for Lynch syndrome in gynecological cancer of a single-center investigation	68
CN26 Do patients with advanced lung cancer have more palliative care needs than patients with severe chronic obstructive pulmonary disease (COPD)?	66
852P Feasibility and safety of HiDAC in AML patients who have achieved CR with hypomethylating agents: Prospective study	66
285P Reticulocyte hemoglobin equivalent as an early predictor of iron deficiency anemia in cancer patients	66
85P Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): A prospective, multicenter, observational study (ELIXI	66
952P Prognostic implication of serum alpha-fetoprotein in patients with unresectable hepatocellular carcinoma treated with regorafenib	65
P-145 Doublet regimen plus anti-vascular endothelial growth factor drug regimen after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer	65
944P Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC II and III stage: A single-center prospective phase II trial	65
P-146 Clinical usefulness of next generation sequencing by liquid biopsy for advanced gastric cancer	65
2028TiP Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small ce	64
1638P Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age	64
464P Exome sequencing of ctDNA portrays the mutational landscape of patients with relapsing colon cancer and indicates new actionable targets	63
169TiP Tocilizumab, ipilimumab, and nivolumab for the treatment of advanced melanoma, non-small cell lung cancer, or urothelial carcinoma	63
589P Patient centricity in cancer: Overview past and current applications of patient reported outcomes	62
LBA32 Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer (phase II): Safe and effective in both PD-L1 positi	62
596P Innovative multimodal deep-learning model for real-time prediction of recurrence in early-stage NSCLC	62
966P Diabetes therapy burden as proxy of impairment of immune checkpoint inhibitors efficacy	62
LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer	62
554P Clinical outcomes of treating patients in prone compared to supine position for breast radiotherapy: A systematic review and meta-analysis	61
643P Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with ALK-rearranged non-small cell lung cancer (ALK+ NSCLC): Second interim analysis of ALCURE	61
709P The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in NSCLC patients with PD-L1 expression of 1% to 49%	60
781P Prognostic role of targeted amino acids as oncometabolites in acute lymphoblastic leukemia	60
699P Osimertinib combined with chemotherapy as first-line treatment in EGFR-mutant advanced NSCLC patients: The first real-world analysis in China	60
546P Multifaceted challenges in patient-centered oral cavity cancer care: An Asia-Pacific cross-sectional study with patients, caregivers, and healthcare professionals	59

259P Irinotecan liposome-based regimen in Chinese patients with advanced pancreatic cancer: A prospective, multi-center, observational real-world study	59
231P CT image-based artificial intelligence quantification of intratumoral heterogeneity for predicting treatment response to immunotherapy combined with anti-angiogenic drugs in hepatocellular carcin	59
349P Predictive gene signature in primary prostate cancer associated with regional lymph-node metastasis using both mRNA and miRNA profiling	58
415P Preliminary safety and efficacy results from phase II study pulsed radiotherapy with tislelizumab in patients with recurrent head & neck cancer	57
475P Impact of palliative care on the quality of life in advanced non-small cell lung cancer patients: A longitudinal study	56
483MO RNA-based multiplex polymerase chain reaction and sequencing to detect fusion genes in melanoma	56
387P COL4A6 promotes tumor progression and chemoresistance in ovarian cancer by activation DDR1 pathway	55
237P Radiotherapy with or without Immune checkpoint inhibitors and tyrosine kinase inhibitors in hepatocellular carcinoma with severe macrovascular invasion: A retrospective cohort study	55
503P Retrospective evaluation of real-world experience and usefulness of implementing next-generation sequencing in clinical oncology: Insights from a developing Asian country	55
339P Comparison of stereotactic body radiation therapy(SBRT) and radical prostatectomy (RP) in high-risk/very high-risk prostate cancer: A large multi-center comparative analysis using propensity scor	55
217P The efficacy and safety of tislelizumab as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after radical reaction	54
482MO Clinical usefulness of next-generation sequencing for metastatic or unresectable gastric cancer in molecular profiling-guided therapy era	54
131MO Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported	54
162P Efficacy of perioperative FLOT in gastric carcinoma and gastroesophageal junction carcinoma in achieving PCR: Retrospective analysis in a single institution experience	54
178P KEYNOTE-859 update: Pembrolizumab + chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer	54
344P Treatment intensification patterns in Asian patients with metastatic hormone sensitive prostate cancer (mHSPC)	54
193P DCLK1’s kinase activity drives its pro-stemness effect in esophageal squamous cell carcinoma	53
565P Prevalence of multi-drug resistant bacteria among neutropenic cancer patients and its association with 30-day mortality: A single centre study from a regional cancer centre	53
501P Comparison between tissue and ctDNA for detecting tumor mutation burden (TMB) across solid tumors: A single centre study from India	53
581P Informal caregiver mental health and time cost for stomach and pancreatic cancer care	52
517P Circulating tumor DNA dynamics to predict response to tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer: An interim report	52
1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition i	50
557P Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals	49
CN107 The effect of Orem-based oral self-care protocol on high-dose chemotherapy-related oral mucositis and self-care agency in patients for hematologic malignancies: A randomized controlled study	49
CN16 Periodontal disease and cancer risk: A nationwide population-based cohort study	49
653P A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors	49
1017P Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)	49
CN66 Healthcare needs, experiences of cancer care, and attitudes towards cancer among ethnic Chinese immigrants in Scotland	48
473P A novel machine learning (ML) model integrating clinical and molecular data to predict response to second-line treatment in recurrent IDHwt-glioblastoma (rGBM)	48
761P Anti-angiogenic therapy in first-line treatment of low-grade serous ovarian cancer: Exploratory meta-analysis of the prospective AGO-OVAR 11/12/16 studies	46
727P Real-world efficacy and safety of cadonilimab in recurrent or metastatic cervical cancer: A multicenter retrospective analysis in China	46
897P Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma	46
574P First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 + bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study	46
850MO Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A tria	45
666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients	45
1011P Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with adva	45
907P Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carci	45
58P Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-bas	44
256P Protein signature of tertiary lymphoid structure predicts efficacy of neoadjuvant chemotherapy in triple-negative breast cancer	44
1093P Preliminary biomarker analysis in the phase III PIVOTAL study: Evidence for the mechanism of action of daromun in melanoma	44
28P Targeting YAP1 as a biomarker of resistance and therapeutic strategy in melanoma immunotherapy	43
138P Toward predicting immune checkpoint blockade response in oesophageal squamous cell carcinoma: Integrating tumour and blood characteristics	43
CN11 The challenges of the multidisciplinary work of nurses in the international department at Gustave Roussy Cancer Campus	43
87P Application of tissue and liquid-based next generation sequencing (NGS) for comprehensive genomic profiling: Evaluating the clinical value of ctDNA technology in treatment decision making	43
1748P A prospective, phase II study of tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult oft tissue sarcoma (TEASTS)	42
418P Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer	42
1121P Artificial Intelligence to predict BRAF mutational status from whole slide images in melanoma	42
978P Efficacy and safety analysis of transarterial chemoembolization combined donafenib with or without immune checkpoint inhibitors in for unresectable hepatocellular carcinoma (HCC): A prospective,	42
1768P Desmoid tumors: Experience of a Spanish reference center	42
1069TiP A phase I/IIa dose escalation and expansion study of 23ME-01473, an anti-ULBP6/2/5 antibody, for patients with advanced solid malignancies	42
1203P Analytical evaluation of whole genome sequencing for acute myeloid leukemia	41
1163P Prognostic value of systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)	41
1182P Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform	41
1248P Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC: LAURA China cohort analysis	40
1739P Linnovate: A phase I/II study of safety/efficacy using lurbinectedin combined with ipilimumab and nivolumab for advanced soft tissue sarcoma (NCT05876715) - Interim analysis of phase I part	40
1339P Impact of KRAS, STK11, and KEAP1 co-mutations on survival outcome and response to chemoimmunotherapy in patients with metastatic NSCLC	40
1385P Uncovering resistance mechanisms and vulnerabilities of KEAP1 mutated lung adenocarcinoma	39
1270P Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A single-arm, phase II multi-center trial	39
1917P Updated survival and vaccine response from the NIPU trial: A randomised, phase II study evaluating nivolumab and ipilimumab with or without UV1 vaccination in patients with pleural mesothelioma	39
1145MO CVM-005: Phase IIa study of CVM-1118, a novel oral anti-vasculogenic mimicry (VM) agent, in advanced neuroendocrine tumors (NET) after progression on prior therapy	39
1863P Circulating biomarkers for risk stratification of cancer patients with chemotherapy associated febrile neutropenia	39
1632P Impact of androgen pathway inhibitors on cognitive function in elderly patients with metastatic prostate cancer: Results from the COG-PRO trial	39
229TiP A phase II trial of a neural network-based treatment decision support tool in patients (pts) with refractory solid organ malignancies	38
211P GynePDX: A new platform of preclinical models for endometrial and ovarian cancers	38
1925MO Regomune study: A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC)	38
1990P MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study	38
2009P PUNCH02: Primary results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response (c	38
199P Association of homologous recombination deficiency status with outcomes for ovarian cancer patients treated with olaparib, and exploration of other biomarkers of relapse and survival	38
1906P ESMO-ESTRO consensus recommendations regarding the safety of combining radiotherapy with targeted agents or immunotherapy	38
1915P Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma	38
331MO Comparing data distribution and prognosis of acute myeloid leukemia according to 5th WHO classification and international consensus	37
1913P Five year results of transbronchial microwave ablation of lung malignancies with electromagnetic navigation guidance	37
MO48-4 Efficacy and quality of life in blinatumomab treatment in patients with acute lymphoblastic leukemia: Systematic review	37
365P Radiotherapy treatment outcomes and treatment compliance of nasopharyngeal cancer patients in Sabah: A retrospective analysis	37
MO60-4 Tryptophan is the prognostic factor in patients with unresectable pancreatic cancer	37
2007P Similar genetic profile in early and late-stage urothelial tract cancer suggests that early genomic testing bears the potential of timely personalized treatment in clinical trials	37
MO36-5 Non-familial prospective risk factors in predicting cancer of unknown primary: A systematic review and meta-analysis	37
622P A prognostic and immune infiltration analysis of CCL26 in pan-cancer	37
CN100 Scalp cooling in breast cancer: What are women's experiences? A description and qualitative study	37
268P Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study	37
375P Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital	36
MO20-3 Outcome of parameningeal head and neck rhabdomyosarcoma in adults: Kyushu Medical Oncology Group Study	36
MO1-6 Steroid-resistant and refractory irAEs requiring additional immunosuppressants to steroids in advanced NSCLC patients	36
201P A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma	36
402O A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary	35
JS01-3 Optimizing cancer genome medicine in clinical practice in Japan	35
MO68-4 A chemoproteoinformatics approach demonstrates that aspirin increases sensitivity to MEK inhibition by directly binding to RPS5	35
195P Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis	35
213P Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastati	35
MO6-5 Tumor microenvironment and clinical efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma	35
505P Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial	35
MO23-5 A retrospective study of the management of distal lower extremity deep vein thrombosis in patients with cancer	34
34P Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer	34
MO5-1 Efficacy and safety of olaparib as a potential treatment for patients with pancreatic cancer: a systematic review	34
451P The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia	34